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Sumanry Of a cohort of 634 children treated from 1942 to 1969 at the Gustave Roussy Institute for a first
cancer and alive 5 years after treatment, 32 later developed second malignant neoplasms (SMN). A case-
control study was performed to determine the relationship between the dose of radiotherapy received on a
given anatomical site for the treatment of a first cancer, and the risk of SMN development at the same
anatomical site. Another aim of the study was to analyse the effects of the association of radiotherapy with
chemotherapy on the risk of SMN. The 32 cases of second malignant neoplasms were individually matched
with one to nine patients of the cohort (a total of 162) who did not develop a SMN after a first cancer,
matching on age, sex, type of first cancer and follow-up duration. The doses of radiotherapy delivered for the
treatment of the first cancer were retrospectively estimated at the 26 anatomical sites of SMN. When the
SMN was a leukaemia, the mean active bone-marrow dose was estimated as a weighted mean of the doses
received by 20 bone sites. As compared to anatomical sites in children who had not received radiotherapy, the
sites which had received 5OGy or more had a relative risk of SMN of 5.8 (P<0.05). When taking into
account the dose received at the site of the SMN, neither the number of fractions nor the type of radiations
were related to the nrsk of SMN. Children who had received chemotherapy had a relative risk of SMN of 2.7
(95% CI: 1.2-6.4), adjusted for the dose of radiotherapy, as compared to those who had not. The relative risk
of SMN did not vary with the dose nor the duration of the chemotherapy. Dactinomycin was found to
increase the relative risk of second soft tissue and bone sarcomas. Cyclophosphamide was found to be less
carcinogenic than the other alkylants. The relative risk of SMN was equal to 2.0 (n.s.) after radiotherapy of
more than 25Gy, to 4.4 (n.s.) after chemotherapy, and to 21.4 (P<0.01) after the combination of these two
treatments modalities, as compared to patients treated by surgery alone. This study suggests that the
oncogenic effect of radiations might be increased by chemotherapy, and that the combination of the two
treatment modalities might be one of the major factors responsible for overall risk of SMN.
The study of the carcinogenic effects of radiotherapy and
chemotherapy is of major clinical interest, because these
treatments may be responsible for a great part of the second
malignant neoplasms (SMN) which occur after a first cancer
(Tucker et al., 1984). It is also useful in theoretical studies
about carcinogenicity because therapeutic exposure to radia-
tions and to cytostatic agents is much more precisely docu-
mented than environmental and professional exposures. The
study of SMN occurring after a first cancer in childhood is
particularly interesting because children may survive for a
long period of time after the treatment of a first cancer, at
ages where the natural incidence of cancer is very low, and
where most environmental factors are less likely to produce
an effect.
Few studies have been published on the relationship
between the risk of SMN and the doses of radiotherapy
received at the anatomical site where the SMN occurred. The
reason is that such studies require precise information on
treatments administered sometimes several decades ago, ena-
bling an estimation of doses delivered at the anatomical sites
of later SMN development. The only published studies
concerning such relationships about SMN after cancer in
childhood are those from the Late Effect Study Group
(LESG). It showed that the risk of second leukaemia after
cancer in childhood was increased by chemotherapy but not
by radiotherapy (Tucker et al., 1987a), that the risk of
second bone sarcoma was increased both by radiotherapy
and chemotherapy (Tucker et al., 1987b), and that the risk
of second thyroid carcinoma was increased by radiotherapy,
but not by chemotherapy (Tucker et al., 1986). These three
types of SMN represent 40-50% of all the SMN (Tucker et
al., 1984; Hawkins et al., 1987; Meadows et al., 1985), 30-
45% when retinoblastomas as a first cancer are excluded
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(Hawkins et al., 1987; Meadows et al., 1985). No studies
have been published concerning the other types of SMN
after cancer in childhood.
We performed a case-control study in a cohort of patients
treated for a first cancer in childhood. The aim of the study
was to analyse the effects of chemotherapy and radiotherapy
received by a given anatomical site, on the nrsk of SMN.
Materials and methods
Patients
Out of a cohort of 634 children (aged under 17) treated
for a first cancer between 1943 and 1969 at the Gustave
Roussy Institute. and alive 5 years after first cancer treat-
ment. 32 have developed 35 SMN. Three patients succes-
sively developed two SMN, and only the first SMN is taken
into account in this report.
Of these 32 patients, 17 were males and 15 were females.
The median age at diagnosis of first cancer was 6 years
(range: 0-14). The most frequent types of first cancer were
neuroblastomas and nephroblastomas. The most frequent
types of SMN were thyroid carcinomas and bone sarcomas,
each represented by six cases (Table I). The median delay
between the first cancer and the SMN was 17 years
(Table I). Three cases had known genetic syndroma which
may constitute a predisposition to developing SMN: one had
a Reklinghausen syndroma, one a naevoid basal cell carci-
noma and one a Turcot syndroma.
The 32 cases of SMN were individually matched with one
to nine children (a total of 162) of the cohort who did not
develop a SMN. Matching criteria were age at first cancer
(+3 vears). sex. type of first cancer and follow-up duration.
The case of retinoblastoma as first cancer was a bilateral one
and has been matched with bilateral retinoblastomas.
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Table I Characteristics of the 32 patients who developed a second malignant neoplasm and of their controls matched on type of
first cancer, sex, follow-up period and age at first cancer (±2 years)
Site of
the second Years between No. of controls
malignant Type offirst Age at first 1st and 2nd
neoplasm cancer Sex cancer (years) cancers RT CT Total With RT With CT
Thyroid Neuroblastoma M < 1 26 Y N 2 2 1
Thyroid Neuroblastoma M 1 22 Y N 7 4 4
Thyroid Neuroblastoma F 2 18 Y N 8 8 3
Thyroid NHL M 9 19 Y N 5 4 5
Thyroid Rhabdomyosarcoma M 10 8 Y Y 4 2 1
Thyroid Medulloblastoma M 6 16 Y Y 6 6 1
Bone NHL M 8 11 Y Y 4 4 2
Bone Ewing's sarcoma M 12 11 Y Y 5 4 2
Bone Retinoblastoma F <1 14 Y Y 2 2 1
Bone Wilm's tumour M 2 9 Y Y 8 8 8
Bone Rhabdomyosarcoma F 5 12 Y Y 8 6 2
Bone Ewing's sarcoma M 8 26 Y N 1 1 0
Breast Adrenal carcinoma F 5 19 N Y 2 2 2
Breast Neuroblastoma F < 1 27 Y N 5 5 1
Skin Neuroblastoma F 14 23 Y N 2 2 2
Skin Medulloblastoma F 10 22 Y Y 5 5 0
Skin Thyroid carcinoma F 13 31 Y N 3 3 0
Skin Brain tumour F 14 12 Y N 5 5 1
Skin Rhabdomyosarcoma M < 1 7 Y N 7 5 2
Brain Brain tumour M 6 11 Y N 8 8 0
Brain Wilm's tumour F 1 22 Y N 5 5 2
Brain Rhabdomyosarcoma F 1 22 Y Y 7 2 1
Stomach Hodgkin's disease M 12 19 Y Y 4 4 2
Soft tissue Neuroblastoma M <1 19 Y Y 7 5 6
Soft tissue Ewing's sarcoma M 5 28 N Y 1 1 0
Soft tissue Rhabdomyosarcoma F 11 16 Y Y 6 2 2
Soft tissue Hodgkin's disease F 11 13 Y Y 5 5 0
Soft tissue Wilm's tumour M 2 11 Y Y 8 7 4
Lymph nodes Skin melanoma F 6 10 N N 2 2 0
Parotid Hodgkin's disease F 14 8 Y Y 4 3 3
AML Hodgkin's disease M 10 10 N Y 7 6 5
ALL Clear cell ca kidney M <1 22 Y Y 9 9 3
F, female; M, Male; Y, yes, N, no; RT, radiotherapy; CT, chemotherapy; NHL, non-Hodgkin's lymphoma; AML, acute
myeloblastic leukaemia; ALL, acute lymphoblastic leukaemia; ca, carcinoma.
For one case of SMN who had had a neuroblastoma at
the age of 14 and later developed a basocellular carcinoma,
no control matched on age was available. This case was
matched on sex and follow-up duration with two controls
aged less than 1 year. It was verified that the results did not
vary when this case and its controls were excluded.
The diagnoses of first and second malignant neoplasms
were confirmed by histology, cytology or tumour markers, in
most cases, and by a review of medical records when a
tumour sample was not available, as in the case of brain
stem tumours.
Radiation dosimetry
For each of the cases of SMN or controls who had received
radiotherapy, the doses were calculated at 60 anatomical
sites of the body, including the 26 where a SMN was
observed in the cohort.
From the size of each child, the positions of the 60
selected sites at time of treatment were estimated using a
mathematical model of child phantom described elsewhere
(Franqois et al., 1988a).
The individual genuing conditions of exposure were
obtained from technical and medical records of the Gustave
Roussy Institute. The doses received at the 60 sites were
calculated using a mathematical model checked experimen-
tally (Francois et al., 1988b). This model describes the
variation of the dose outside the field axis. It takes into
account the type of the radiotherapy, the characteristics of
the collimator and the scattered radiation. Calculations have
been compared with measurements performed at the M.D.
Anderson Hospital in Houston with anthropomorphic phan-
toms, and a high degree of concordance has been observed
(Francois et al., 1988b). The mean dose received at the bone
marrow level was estimated as a weighted mean of the doses
received at 20 bone sites, using published age-dependent
coefficients (Christy et al., 1981). For the cases of second
unilateral thyroid carcinoma, the dose calculated was the
dose received by the lobe of the thyroid where the SMN
developed.
Chemotherapy quantification
The dose of each chemotherapeutic agent received by the
cases and the controls for the initial treatment or for
recurrences of the first cancer (local relapses or distant
metastases), and the duration of treatment cycles were
abstracted from the medical records of the Gustave Roussy
Institute. For each drug, the total dose per square metre of
body surface was calculated for each child. For drugs which
had been given to more than five children, a score for the
drug was defined as 1 for a child having received less than
the median dose, 2 for a child having received a dose equal
to or higher than the median, and 0 for a child who had not
received the drug. For drugs administered to five children or
less, the score was 1 for a child who had received the drug
and 0 otherwise. The chemotherapeutic score of each child
was defined by the addition of the scores obtained for each
drug. An alkylator score was defined similarly, where the
alkylants were only taken into account.
Statistical methods
Comparisons between cases and controls were made using
the conditional logistic regression method (Breslow & Day,
1980). The expressions 'relative risk' and 'matched relative
odds' are used indifferently. All confidence intervals (CI) are
95% confidence intervals.794 F. DE VATHAIRE et al.
Results
Four cases (13%) and 24 controls (15%) had had a relapse
of first cancer, and five cases (16%) and 23 controls (14%)
had had metastases. These events were not found to have
any significant influence on the relative risk of SMN.
Radiotherapy
Twenty-eight cases (88%) and 137 controls (84%) had been
treated by radiation. Of the 28 SMN which had developed in
irradiated patients, 18 were inside the irradiated volume and
10 developed outside of it.
Five types of radiotherapy were used as first cancer
treatment: orthovoltage (200kV), cobalt-60, high energy X-
rays, electrons, and brachytherapy (Table II). The most
frequent types of energy employed were cobalt and orthovol-
tage. Table III gives the relative risk of SMN development
as a function of the dose of radiotherapy at the anatomical
site of the SMN and of the administration of chemotherapy.
Table 11 Radiotherapy received by the cases of second malignant
neoplasms and the matched controls
Cases (32) Controls (162)
Radiation No (0) No (°o)
Orthovoltage (200kV) 13 (41) 77 (47)
Cobalt 10 (31) 45 (28)
High energy X-rays 3 (9) 19 (12)
Electrons 2 (6) 10 (6)
Brachytherapy 3 (9) 3 (2)
All techniques 28' (88) 137a (84)
'Some patients had received more than one type of radiation.
Whether chemotherapy was controlled or not. a dose-
response gradient was observed for the radiotherapy. When
the dose received at the SMN site was taken into account.
neither the type of energy nor the number of fractions were
found to be related to the risk of SMN.
Chemotherapy
Nineteen cases (59%) and 66 controls (40%) had received
chemotherapy. Four cases (13%) and 26 controls (14%) had
received more than one drug (two cases and five controls
had received MOPP, i.e. nitrogen mustard, vincristine, pro-
carbazine and prednisone, for treatment of Hodgkin's dis-
ease). Details on chemotherapies are given in Table IV.
Children who had received chemotherapy had a relative
nsk of SMN of 2.7 (CI: 1.2-6.4), compared to those who
had not. The relative risk of SMN, adjusted for radio-
therapy, was not found to be dependent on the chemother-
apy score: 2.7 for a score equal to 1, 3.0 for a score equal to
2, and 1.4 for a score greater than 2. The relative risk of
SMN was not found to be dependent on the duration of the
chemotherapy either 2.4 for a duration of less than 3
months and 2.9 for a duration of 3 months or more. These
results remained unchanged when the effects of the alkylants
were considered alone.
Table V shows the relative risk of SMN according to the
type of chemotherapy. As compared to patients who had not
received chemotherapy, the relative risk of SMN was not
significant for patients who had received cyclophosphamide
as the only alkylant or non-alkylants other than Dactino-
mycin. The relative risk of SMN for administration of
Dactinomycin as the only drug was particularly high
(RR=8.7, P<0.01). The relative risk for the administration
Table Ill Matched relative risk (RR) of second malignant neoplasms (SMN) by chemotherapy
and by dose of radiotherapy received at the site of the SMN of case and at the same site for
matched controls
Dose of radiotherapy (Gy) at SMN site
Chemotherapy 0 0.01-0.9 1-9.9 10-24.9 25-49.9 50+ P ralue'
No J
Cases, controls 11l4 533 3 25 2,8 2/16
RR of SMN ib 2.0 2.3 3.7 2.0 0.6
Yes
Cases,controls 3 11 3 20 2 16 4A11 7/8
RR of SMN 4.4 2.3 3.6 9.2 21.4 <0.01
Total
Cases,controls 4,25 8,53 5 41 6,19 519 4/5
RR of SMN ib 1.1 1.2 2.5 2.6 5.8 0.02c
'Test for trend; bReference category, 'Adjusted on chemotherapy.
Tabe IV Drugs received by the cases of second malignant neoplasms and the matched controls
Cases (2) Controls (162)
Doses (mgm-2) Doses (mgm -2)
Drugs No. (o) Median Range No. (%) Median Range
Alkylating agents
Cyclophosphamide 2 (6) 3,900 (1,150-7,800) 21 (13) 4,800 (875-48,000)
Nitrogen mustard 2 (6) 127 (100-154) 8 (5) 60 (2-96)
Procarbazine 4 (13) 6,100 (2,200-27,000) 8 (5) 5,719 (800-10,900)
Chlorambucil 1 (3) 11,300 3 (2) 1.100 (243-1,100)
Melphalan 2 (6) 9,030 (60-18,000) 2 (1) 523 (45-1,000)
Other alkylants 2 (6) - 4 (2)
Any alkylant 9 (28) - 33 (20) -
Dactinomycin 8 (25) 3.5 (1.9-15.8) 28 (17) 2.3 (0.1-13.5)
Methotrexate 3 (9) 1,550 (780-3,318) 5 (3) 275 (33-800)
Vinca alkaloids 4 (13) - 22 (14) -
Other non-alkylant 0 - 4 (2)
Any drug 19 (59) 66 (40)RISK OF SECOND CANCER AFTER CHILDHOOD CANCER
Table V Matched relative risk (RR) of second malignant neoplasm (SMN) by type of chemotherapy and by
dose of radiotherapy received at the SMN site of the case, and at the same site for matched controls
Dose of radiotherapy at the SMN site
0-9.9Gy 10Gy+ Total
Type of chemotherapy RR (No.) RR (No.) RR (No.)
None f (9/72) (4/24) lb (13/96)
Cyclophosphamide la 1.9
or non-alkylant (except Dactinomycin) (0/20) (3/8) 0.8 (3/28)
Dactinomycin only 6.7a (5/18) 33.6b (3/4) 8.7b (8/22)
Alkylants other than cyclophosphamide+others 2.6 (3/9) 8.9b (5/7) 3.6 (8/16)
No. number of cases of SMN/number of controls. ap<0.05; bp<0.01. la, reference category for the risks by
doses of radiotherapy and by type of chemotherapy. lb, reference category for the risks by types of
chemotherapy, adjusted on radiotherapy.
of alkylants other than cyclophosphamide was nearly signifi-
cant (RR =3.6, P =0.06). When the dose of radiotherapy
received at the SMN site was considered, the relative risk of
SMN for administration of Dactinomycin as the only drug
was significant even for doses of radiotherapy below 10Gy
(RR =6.7, P<0.05) (Table V).
Type of second malignancies
All the six patients who developed a second thyroid carci-
noma had been treated with radiotherapy (doses at the
thyroid in Gy: 0.2, 0.5, 0.6, 13.2, 13.8, 15.3; median 6.9).
Twenty-six of the 32 corresponding controls had received
radiotherapy (doses at the thyroid in Gy: range 0.1-26.4;
median 0.9). Each case had received to the thyroid a median
of 0.2Gy more than his or her matched controls (range of
the differences in Gy: - 14.9 to +25.9). The relative risk of
second thyroid carcinoma for a dose higher than 2Gy was
5.1 (CI: 0.5 to 62). Two of the six cases had also received
chemotherapy (one Dactinomycin and one methotrexate), as
compared to 15 of the 32 controls.
The six cases of second bone sarcoma had been given
radiotherapy (doses at the bone sites in Gy: 0.1, 0.4, 17.6,
36.6, 56.2, 62.3; median 27.1). Twenty-five of the 28 corres-
ponding controls had been given radiotherapy (doses at the
bone sites in Gy: range 0.1 to 58.5; median: 0.3). Each case
had received to the bone site of SMN a median of 0.5 Gy
more than his or -her matched controls (range of the
differences in Gy: -62.3 to +23.3). The relative risk of
second bone sarcoma for a dose of 10Gy or more was 4.8
(CI: 0.5 to 46). Five of the six cases had received chemo-
therapy, four with one single agent (two Dactinomycin, one
cyclophosphamide, one methotrexate), and the fifth one with
four agents (melphalan, cyclophosphamide, methotrexate,
vincristine), as compared to 15 of the corresponding 28
controls.
Four of the five cases of second soft tissue sarcoma had
been given radiotherapy (doses received at the soft tissue
site, in Gy: 10.9, 24.4, 40.2, 56.5; median 32.3), as compared
to 20 of the 27 corresponding controls (range 0.1 to 110.7;
median 6.5). Each case had received to the soft tissue site of
SMN a median of 13.2Gy more than his or her matched
controls (range of the differences in Gy: -56.3 to +70.5).
All the cases had been administered chemotherapy: Dactino-
mycin alone for three, sarcolysine alone for one, and pro-
carbazine for one, as compared to 12 of the 27 controls. The
risk of second soft tissue sarcoma was multiplied by 6.6
(P=0.4) with Dactinomycin and by 7.2 (P=0.02) with
alkylants.
One of the two cases of second leukaemia had had
radiotherapy (dose at the active bone-marrow level: 1.7Gy),
as compared to 15 of the 16 corresponding controls (range
0.5 to 12.5; median 2.OGy). Both the cases had had chemo-
therapy (Dactinomycin alone for one, MOPP, chlorambucil
and vinblastine for the other), as compared to eight of the 16
corresponding controls.
If second bone sarcomas, thyroid carcinomas and leukae-
Table VI Matched relative risk (RR) of second malignant neo-
plasms (SMN) by chemotherapy and by dose of radiotherapy
received at the SMN site of the case and at the same site for
matched controls, excluding second bone sarcomas, thyroid carcino-
mas and leukaemias
Dose of radiotherapy at the SMN site
0-9.9Gy 10Gy+ Total
Chemotherapy RR (No.) RR (No.) RR (No.)
No la (7/36) 0.3 (1/22) lb (8/58)
Yes 0.9 (3/21) 15.4a (7/7) 3.1 (10/28)
Total ic (10/57) 1.1 (8/29)
No., number of cases of SMN/number of controls; ap=0.05; la,
reference category for the risks by doses of radiotherapy and by
chemotherapy; Ib, reterence category for the risk tor chemotherapy,
adjusted on radiotherapy; lc, reference category for the risk by
doses of radiotherapy, adjusted on chemotherapy.
mias are excluded, results concerning the 18 remaining cases
were similar to those obtained with all of the 32 cases. The
relative risk associated with the administration of chemo-
therapy was 3.2 (CI: 1-15). Neither the score nor the
duration of the chemotherapy were found to be related to
the relative risk of SMN. As compared to children who had
received no chemotherapy or less than 10Gy of radiother-
apy, those who had received 10Gy or more at a given
anatomical site and had been given chemotherapy had a
relative risk of SMN of 15.4 (P=0.02) at this anatomical site
(Table VI).
Discussion
This study showed that the combination of high doses of
radiotherapy with chemotherapy, particularly with alkylants,
increased the risk of SMN after cancer in childhood. The
effect of this association remained even when second bone
sarcomas, thyroid carcinomas and leukaemias, which have
already been studied in a much larger cohort by others
(Tucker et al., 1986, 1987a,b), were excluded. Cyclo-
phosphamide seemed to be less oncogenic than other alky-
lants. Dactinomycin seemed to be more oncogenic than other
non-alkylants, particularly for second bone and soft tissue
sarcoma.
We did not find that the risk of SMN increased with the
dose or the duration of the chemotherapy. In our series, only
few children received the most carcinogenic drugs (i.e. alky-
lants, other than cyclophosphamide), and they were given
much smaller doses than the current doses administered. The
long-term consequences from current treatment modalities
will be seen in a decade or later.
One of the aims of this study was to evaluate the
relationship between the dose received at a given anatomical
site and the risk of SMN. We cannot compare our results
with similar results from other authors because the only
published studies using the same methodology, i.e. the
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calculation of the dose received at the site of the SMN
development, did not consider the risk of all the second
malignant neoplasms, but only given types of SMN.
The risk of SMN was not found to be related to the type
of radiation (mainly megavoltage versus orthovoltage).
whether the dose received at the site of the SMN was
controlled or not. This result is in agreement with the report
from the LESG (Tucker et al., 1986, 1987b), but differs from
that of Potish. who observed a higher n'sk of SMN after
irradiation by orthovoltage than by megavoltage (Potish et
al., 1985).
We found that the risk of SMN was lower when the
children had been given cyclophosphamide than when they
had been given another alkylants. Only two cases of SMN
(both bone sarcomas) had had cyclophosphamide. The low
risk of SMN other than second bone sarcomas associated
with cyclophosphamide, as compared to other alkylants is in
agreement with the observation that melphalan is more
leukemogenic than cyclophosphamide after ovarian cancers
(Greene et al., 1986) or myelomatosis (Cuzick et al., 1987).
The fact that cyclophospharmide increases the risk of bone
sarcomas has been reported by the LESG (Tucker et al.,
1987b) and Hawkins (Hawkins et al., 1987).
We found that the administration of Dactinomycin
increases the risk of SMN, even when it was not associated
with high doses of radiotherapy at the site of the SMN.
Dactinomycin was particularly associated with second bone
sarcomas (two cases) and soft tissue sarcomas (four cases).
This result is in agreement with the LESG observation that
the risk of second bone sarcoma was increased by Dactino-
mycin (Tucker et al., 1987b), and in contradiction with the
protective effect of Dactinomycin on the risk of SMN. as it
has been suggested (D'Angio et al., 1979).
Out of retinoblastomas, three of the 32 cases of SMN and
five of the 162 controls of our study had a known genetic
predisposition to develop SMN. When these patients were
excluded, the results were similar to that obtained with the
whole group of the patients. The study of identified or still
unidentified genetic predispositions to develop SMN, as well
as the study of the associations between a given type of first
cancer and a given type of SMN, were not the purpose of
this analysis.
In conclusion this study shows that the association of high
doses of radiotherapy with alkylants is probably one of the
major risk factors for SMN.
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